Literature DB >> 7618718

Are all effects of esmolol equally rapid in onset?

E Ornstein1, W L Young, N Ostapkovich, R S Matteo, J Diaz.   

Abstract

The purpose of this study was to compare the time course of the bradycardic and hypotensive effects of esmolol. Ten patients undergoing craniotomy requiring hypotension were anesthetized with nitrous oxide and isoflurane. During steady state anesthesia, the response to an infusion of esmolol 500 micrograms.kg-1.min-1 for 90 s followed by 300 micrograms.kg-1.min-1 was measured over 60 min. Heart rate (HR), mean arterial pressure (MAP), and plasma renin activity (PRA) responses did not occur with equal rapidity. The half-time for the 14% decrease in HR (81 +/- 13 bpm to 70 +/- 9 bpm) was 1.2 min. MAP decreased by 26% (85 +/- 7 mm Hg to 63 +/- 6 mm Hg) with a 17.8 min half-time. This delay in MAP response may, in part, be related to the gradual 44% decline in PRA (9.5 +/- 4.5 ng.mL-1.h-1 to 5.3 +/- 2.5 ng.mL-1.h-1) occurring with a half-time of 11.9 min. The times to attainment of 90% maximum decreases were 4.8 +/- 3.0 min for HR, 42.5 +/- 8.9 min for MAP, and 32.1 +/- 15.0 min for PRA. Thus although esmolol has an ultrashort kinetic half-life, only the HR effect can be considered to have an ultrashort onset.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7618718     DOI: 10.1097/00000539-199508000-00015

Source DB:  PubMed          Journal:  Anesth Analg        ISSN: 0003-2999            Impact factor:   5.108


  3 in total

1.  Bolus application of landiolol and esmolol: comparison of the pharmacokinetic and pharmacodynamic profiles in a healthy Caucasian group.

Authors:  Günther Krumpl; Ivan Ulc; Michaela Trebs; Pavla Kadlecová; Juri Hodisch
Journal:  Eur J Clin Pharmacol       Date:  2017-01-13       Impact factor: 2.953

Review 2.  Controlled hypotension: a guide to drug choice.

Authors:  Christian-Serge Degoute
Journal:  Drugs       Date:  2007       Impact factor: 9.546

3.  Dobutamine Alters the Pharmacokinetic and Pharmacodynamic Behavior of Esmolol.

Authors:  Günther Krumpl; Ivan Ulč; Michaela Trebs; Juri Hodisch; Pavla Kadlecová; Bernhard Husch
Journal:  Cureus       Date:  2020-12-22
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.